HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer

References

• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69. doi:10.1126/science.aaa4971.
   PubMed Web of Science ®Google Scholar
• Wirth TC, Kühnel F. Neoantigen targeting-dawn of a new era in cancer immunotherapy? Front Immunol. 2017;8: 1848-1848. doi:10.3389/fimmu.2017.01848.
   Web of Science ®Google Scholar
• Castle JC, Uduman M, Pabla S, Stein RB, Buell JS. Mutation-derived neoantigens for cancer immunotherapy. Front Immunol. 2019;10(1856). doi:10.3389/fimmu.2019.01856.
   Google Scholar
• Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T.The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA. 2005;102(44):16013. doi:10.1073/pnas.0500090102.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Johnson Iii BA, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017;17:209. doi:10.1038/nrc.2016.154.
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–12. doi:10.1038/s41588-018-0312-8.
   PubMed Web of Science ®Google Scholar
• Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008;68(3):889. doi:10.1158/0008-5472.CAN-07-3095.
   PubMed Web of Science ®Google Scholar
• Verdegaal EME, de Miranda NFCC, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, Van Der Minne CE, Schotte R, Spits H, Haanen JB. Neoantigen landscape dynamics during human melanoma–T cell interactions. Nature. 2016;536:91. doi:10.1038/nature18945.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E. The immune landscape of cancer. Immunity. 2018;48(4):812–830.e14. doi:10.1016/j.immuni.2018.03.023.
   PubMed Web of Science ®Google Scholar
• Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 2014;30(23):3310–3316. doi:10.1093/bioinformatics/btu548.
   PubMed Web of Science ®Google Scholar
• Kawaguchi S, Higasa K, Shimizu M, Yamada R, Matsuda F. HLA-HD: an accurate HLA typing algorithm for next-generation sequencing data. Hum Mutat. 2017;38(7):788–797. doi:10.1002/humu.2017.38.issue-7.
   PubMed Web of Science ®Google Scholar
• Torres-García W, Zheng S, Sivachenko A, Vegesna R, Wang Q, Yao R, Berger MF, Weinstein JN, Getz G, Verhaak RG. PRADA: pipeline for RNA sequencing data analysis. Bioinformatics. 2014;30(15):2224–2226. doi:10.1093/bioinformatics/btu169.
   PubMed Web of Science ®Google Scholar
• Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417. doi:10.1038/nmeth.4197.
   PubMed Web of Science ®Google Scholar
• Nielsen M, Andreatta M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med. 2016;8(1):33. doi:10.1186/s13073-016-0288-x.
   PubMedGoogle Scholar
• Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, Sette A, Peters B, Nielsen M. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 2018;154(3):394–406. doi:10.1111/imm.12889.
   PubMed Web of Science ®Google Scholar
• Asmann YW, Middha S, Hossain A, Baheti S, Li Y, Chai H-S, Sun Z, Duffy PH, Hadad AA, Nair A, Liu X. TREAT: a bioinformatics tool for variant annotations and visualizations in targeted and exome sequencing data. Bioinformatics. 2011;28(2):277–278. doi:10.1093/bioinformatics/btr612.
   PubMed Web of Science ®Google Scholar
• Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. ArXiv. 2013;1303:3997v2.
   Google Scholar
• McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–1303. doi:10.1101/gr.107524.110.
   PubMed Web of Science ®Google Scholar
• Kocher J-PA, Quest DJ, Duffy P, Meiners MA, Moore RM, Rider D, Hossain A, Hart SN, Dinu V. the biological reference repository (BioR): a rapid and flexible system for genomics annotation. Bioinformatics. 2014;30(13):1920–1922. doi:10.1093/bioinformatics/btu137.
   PubMed Web of Science ®Google Scholar
• Narang P, Chen M, Sharma AA, Anderson KS, Wilson MA. The neoepitope landscape of breast cancer: implications for immunotherapy. BMC Cancer. 2019;19(1):200. doi:10.1186/s12885-019-5402-1.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214. doi:10.1038/nature12213.
   PubMed Web of Science ®Google Scholar
• Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL, Jablon L, Cobleigh MA. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336(20):1409–1415. doi:10.1056/NEJM199705153362002.
   PubMed Web of Science ®Google Scholar
• Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. JNCI. 1997;89(3):227–237. doi:10.1093/jnci/89.3.227.
   PubMedGoogle Scholar
• King M-C, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and <em>BRCA2</em&gt. Science. 2003;302:643.
   PubMed Web of Science ®Google Scholar
• Wen WX, Leong C-O. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer. PLoS One. 2019;14(4):e0215381. doi:10.1371/journal.pone.0215381.
   PubMed Web of Science ®Google Scholar
• Borg Å, Haile RW, Malone KE, Capanu M, Diep A, Törngren T, Teraoka S, Begg CB, Thomas DC, Concannon P, Mellemkjaer L. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. Hum Mutat. 2010;31(3):E1200–E1240. doi:10.1002/humu.21202.
   PubMed Web of Science ®Google Scholar
• Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400–416.e11. doi:10.1016/j.cell.2018.02.052.
   PubMed Web of Science ®Google Scholar
• Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D’Andrea AD, Matulonis UA. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7:12. doi:10.18632/oncotarget.7277.
   Google Scholar
• Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F, Salim M, Vallon-Christersson J, Törngren T, Kvist A, Ringnér M. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun. 2017;8(1):1738. doi:10.1038/s41467-017-01460-0.
   PubMedGoogle Scholar
• Miller A, Asmann Y, Cattaneo L, Braggio E, Keats J, Auclair D, Lonial S, Russell SJ, Stewart AK. High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. Blood Cancer J. 2017;7(9):e612–e612. doi:10.1038/bcj.2017.94.
   PubMed Web of Science ®Google Scholar
• Rathe SK, Popescu FE, Johnson JE, Watson AL, Marko TA, Moriarity BS, Ohlfest JR, Largaespada DA. Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas. Sci Rep. 2019;9(1): 358-358. doi:10.1038/s41598-018-36840-z.
   PubMedGoogle Scholar
• Wei Z, Zhou C, Zhang Z, Guan M, Zhang C, Liu Z, Liu Q. The landscape of tumor fusion neoantigens: a pan-cancer analysis. iScience. 2019;21:249–260. doi:10.1016/j.isci.2019.10.028.
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Mai TH, Nakamura Y. Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors. J Hum Genet. 2017;62(3):397–405. doi:10.1038/jhg.2016.141.
   PubMed Web of Science ®Google Scholar
• Matey-Hernandez ML, Maretty L, Jensen JM, Petersen B, Sibbesen JA, Liu S, et al. Benchmarking the HLA typing performance of polysolver and optitype in 50 danish parental trios. BMC Bioinf. 2018;19(1):239. doi:10.1186/s12859-018-2239-6.
   PubMedGoogle Scholar
• Abelin JG, Harjanto D, Malloy M, Suri P, Colson T, Goulding SP, Creech AL, Serrano LR, Nasir G, Nasrullah Y, McGann CD. Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction. Immunity. 2019;51(4):766–779.e17. doi:10.1016/j.immuni.2019.08.012.
   PubMed Web of Science ®Google Scholar
• Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L, Erskine CL, Van Keulen VP, Kosari F, Murphy SJ, Ren H. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J Thoracic Oncol. 2019;14(2):276–287. doi:10.1016/j.jtho.2018.10.001.
   PubMed Web of Science ®Google Scholar
• Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8(12):1548. doi:10.1158/2159-8290.CD-18-0804.
   PubMed Web of Science ®Google Scholar
• Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, Sciaranghella D. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407. doi:10.1038/ng.3520.
   PubMed Web of Science ®Google Scholar
• Ostroumov D, Fekete-Drimusz N, Saborowski M, Kühnel F, Woller N. CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cellular and Mol Life Sci. 2018;75(4):689–713. doi:10.1007/s00018-017-2686-7.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348(6230):124. doi:10.1126/science.aaa1348.
   PubMed Web of Science ®Google Scholar